• ProMIS Neurosciences (PMN) will participate in the 2020 BIO CEO & Investor Conference in New York.
  • The company’s Executive Chairman, Eugene Williams, will give a presentation during the conference.
  • Mr Williams will present data which supports the company’s antibody program for neurodegenerative diseases.
  • ProMIS’s share price remains unchanged, with shares trading at $0.22 apiece.

Biotechnology company ProMIS Neurosciences (PMN) will send a representative to attend and participate in the 2020 BIO CEO & Investor Conference.

The 2-day long conference will be hosted at the Marriott Marquis Hotel in New York City.

The event will bring together investors, industry analysts, and senior executives from biotechnology and pharmaceutical companies like ProMIS.

The conference will take place on February 10th and 11th, with company presentations on both days.

The Executive Chairman of ProMIS, Eugene Williams, will give a presentation at 3:00pm (Eastern Time) on February 11th.

In his presentation, Mr Williams will present data that supports ProMIS’ antibody programs for targeting and treating neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and ALS.

Unfortunately, webcasting will not be available for the event.

ProMIS’s share price remains unchanged, with shares trading at $0.22 apiece.

More From The Market Online

Revolutionizing medical imaging with nanocarbon-based contrast drugs

The partnership between Rain Cage Carbon and Voyageur Pharmaceuticals (TSXV:VM) is transforming carbon capture and reuse technology.

Optimi Health completes first MDMA shipment to Israel

Optimi Health (CSE:OPTI) recently touted several milestones it had achieved in its international psychedelic supply operations strategy.

Theralase enhances cancer drug efficacy

Theralase Technologies (TSXV:TLT) announces its Ruvidar compound creates a new compound able to significantly kill more cancer cells.

FDA committee rejects MDMA drug, discounting psychedelic stocks

A committee of the U.S. FDA rejects a drug application to treat PTSD using MDMA-assisted therapy, causing numerous stocks to fall.